Myeloma patient survey to inform development of personalised medicine tool
Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects.
Myeloma Patients Europe (MPE) is running a survey for European myeloma patients to understand their quality of life and how this is impacted by treatment side-effects.
Today marks the official launch of a new international project consortium, known as “CARAMBA”, which will research an innovative immunotherapy for the treatment of multiple myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through…
MPE is inviting members to express their interest in participating in a small pilot on patient information for newly diagnosed myeloma patients. As part of this pilot, MPE will be adapting and translating an Infopack…
Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United…
We all were saddened to hear of our recent loss of Yacob Yacobovitch, who passed away on the 18th of april 2017. Yacob Yacobovitch was member of Myeloma Patients Europe from 2012 until 2016.
It is with great sadness that we share with you that our friend, colleague and Board member Mika Peltovaara (23 Dec 1965 – 21 Febr 2017) passed away in the morning of the 21th of…
London, January 18, 2017.- ADAPT SMART’s General Assembly, held at the European Medicines Agency (EMA), agrees to focus its final year on incorporating stakeholder feedback into the development of Medicines Adaptive Pathways to Patients (MAPPs)…
MPE, in collaboration with other patient organisations, is conducting a project to analyse legal agreements of pharmaceutical companies with patient advocates. The project will make suggestions for simpler, more understandable agreements that would sufficiently reflect…